Puretech Health (LON:PRTC) Rating Reiterated by Peel Hunt

Peel Hunt restated their buy rating on shares of Puretech Health (LON:PRTC) in a research report report published on Tuesday, December 19th. Peel Hunt currently has a GBX 302 ($4.10) target price on the stock.

PRTC has been the subject of several other reports. Liberum Capital reissued a buy rating and issued a GBX 248 ($3.36) target price on shares of Puretech Health in a research note on Thursday, November 30th. Numis Securities raised their target price on shares of Puretech Health from GBX 207 ($2.81) to GBX 233 ($3.16) and gave the company a buy rating in a research note on Thursday, November 30th. Jefferies Group reissued a buy rating and issued a GBX 225 ($3.05) target price on shares of Puretech Health in a research note on Wednesday, August 30th. Finally, N+1 Singer reissued a buy rating on shares of Puretech Health in a research note on Thursday, November 30th. Five equities research analysts have rated the stock with a buy rating, Puretech Health has a consensus rating of Buy and a consensus target price of GBX 252.80 ($3.43).

Puretech Health (LON PRTC) traded down GBX 4 ($0.05) during midday trading on Tuesday, hitting GBX 170.50 ($2.31). 152,678 shares of the stock were exchanged, compared to its average volume of 68,880. Puretech Health has a 12 month low of GBX 110 ($1.49) and a 12 month high of GBX 178 ($2.41). The firm has a market capitalization of $402.78 and a P/E ratio of -897.37.

COPYRIGHT VIOLATION NOTICE: “Puretech Health (LON:PRTC) Rating Reiterated by Peel Hunt” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another publication, it was stolen and reposted in violation of United States & international copyright laws. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/01/13/puretech-health-prtc-earns-buy-rating-from-peel-hunt.html.

About Puretech Health

PureTech Health plc is a cross-disciplinary healthcare company. The Company operates through two segments: growth stage businesses and project phase businesses. Businesses in the growth stage businesses segment are those whose activities focus on developing products to solve healthcare problems in varied markets.

Analyst Recommendations for Puretech Health (LON:PRTC)

Receive News & Ratings for Puretech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puretech Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply